Review paper
JC Polyomavirus Infection Potentiated by Biologics
Volume: 34, Issue: 2, Pages: 359 - 388
Published: Jun 1, 2020
Abstract
The risk of JC polyomavirus encephalopathy varies among biologic classes and among agents within the same class. Of currently used biologics, the highest risk is seen with natalizumab followed by rituximab. Multiple other agents have also been implicated. Drug-specific causality is difficult to establish because many patients receive multiple immunomodulatory medications concomitantly or sequentially, and have other immunocompromising factors...
Paper Details
Title
JC Polyomavirus Infection Potentiated by Biologics
Published Date
Jun 1, 2020
Volume
34
Issue
2
Pages
359 - 388
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History